Related Experiment Video
Updated: Aug 9, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
Published on: May 15, 2019
Lenalidomide: an immunomodulatory drug
1H Lee Moffitt Cancer Center and Research Institute, and the University of South Florida College of Medicine, Malignancy Hematology Program, Department of Interdisciplinary Oncology, Tampa, FL 33612, USA. listAF@moffitt.usf.edu
Abstract:
Lenalidomide (CC-5013; Revlimid) represents one compound in a category of new medications known as immunomodulatory drugs. These compounds are thalidomide derivatives. Through relatively minor structural modifications, the potency of the medication is improved compared with the parent compound, and the side-effect profile has changed considerably. The neurologic toxicity and pro-thrombotic effects of thalidomide are reduced in the structural analog, although concerns regarding pro-thrombotic effects are still present when lenalidomide is combined with dexamethasone. Data supporting lenalidomide's use in myelodysplastic syndrome and multiple myeloma has been published over the past several years and presented at the May 2005 meeting of the American Society of Clinical Oncology. Further trials are ongoing for many other malignancies. This report will review the preclinical and clinical results of the investigations with this exciting new therapeutic, its toxicities and future prospects.
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Immunodeficiency Diseases
There are three main causes of immunodeficiency disorders...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Antiviral Nucleoside Inhibitors
Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
Drugs for Treatment of Ulcerative Colitis in IBD